NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Nirmal Bang Report
Rossari Biotech Ltd.’s Q4 FY24 performance came broadly in-line with our estimates on the back of continued growth in various sections of HPPC segment.
Sequential decline in gross margin (192 basis points) was on account of inferior mix along with moderation in selling prices. The management indicated improvement going forward and expect gross margin to settle at ~30%.
Existing capacity ramp up, commissioning of new capacities along with growth drivers in various sections of HPPC makes a plausible case for double digit volume growth in next two years.
Maintain Buy (25 times price-to-earning FY26E).
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
RECOMMENDED FOR YOU
Sonata Software Q2 Review — Long-Term Story Remains Intact, Says IDBI Capital Maintaining 'Hold'
Bharat Forge Q2 Review: Brokerages Stay Cautious Despite Strong Quarter — Here's Why
Paytm Q2 Review: Yes Securities Maintains 'Add', Revises Target Price — Check Details
GAIL Q2 Review— Tariff Hikes, Volume Uplift Key Catalysts In H2 FY26-27; Motilal Oswal Maintains 'Buy'
POPULAR